Expression and significance of survivin in colorectal high grade and low grade adenomas

Acta Histochemica

Volumn 117, Issue 6, 2015, Pages 590-594

  Adamkov, Marian ^a   Výbohová, Desanka ^a   Tupá, Veronika ^a   Chylíková, Jaroslava ^b   Horáček, Jaroslav ^b   Benčat, Marián ^c  

^a University Hospital in Martin   (Slovakia)

^b UNIVERSITY OF OSTRAVA   (Czech Republic)

^c sro   (Slovakia)

Author keywords

Biomarker; Colon; Prognosis; Survivin; Tubular adenoma

Indexed keywords

SURVIVIN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SIZE; COLON ADENOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING;

EID: 84938741579     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2015.05.006     Document Type: Article

References (33)

1. Adamkov M., Lauko L., Bálentová S., Péč J., Péč M., Rajčáni J. Expression pattern of anti-apoptotic protein survivn in dysplastic nevi. Neoplasma 2009, 56(2):130-135.
2. Adamkov M., Halašová E., Kajo K., Macháleková K., Výbohová D., Varga I., et al. Survivin: a promising biomarker in breast carcinoma. Neoplasma 2010, 57(6):572-577.
3. Adamkov M., Kajo K., Vybohova D., Krajcovic J., Stuller F., Rajcani J. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasma 2012, 59(1):30-37.
4. Alonso G., Lozzi D., Szram H., Romero I., Donadeu y Ros N., Fernandez J.L., et al. Factors, associated with high grade dysplasia and cancer in colorectal adenoma. Acta Gastroenterol. Latinoam. 1995, 25:131-135.
5. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
6. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430:199-205.
7. Bariol C., Hawkins N.J., Turner J.J., Meagher A.P., Williams D.B., Ward R.L. Histopathological and clinical evaluation of serrated adenomas of the colon and rectum. Mod. Pathol. 2003, 16(5):417-423.
8. Barnes N., Haywood P., Flint P., Knox W.F., Bundred N.J. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br. J. Cancer 2006, 94:253-258.
9. Blumberg D. Laparoscopic colon resection of benign polyps: high grade dysplasia on endoscopic biopsy and polyp location predict risk of cancer. Surg. Laparosc. Endosc. Percutan. Tech. 2009, 19(3):255-257.
10. Brennan D.J., Rexhepaj E., O'Brien S.L., Mcsherry E., O'Connor D.P., Fagan A., et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin. Cancer Res. 2008, 14:2681-2689.
11. Chen W.C., Liu Q., Fu J.X., Kang S.Y. Expression of survivin and its significance in colorectal cancer. World J. Gastroenterol. 2004, 10(19):2886-2889.
12. Dallaglio K., Marconi A., Pincelli C. Survivin: a dual player in healthy and diseased skin. J. Investig. Dermatol. 2012, 132:18-27.
13. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:49-60.
14. Euscher E.D., Niemann T.H., Lucas J.G., Kurokawa A.M., Frankel W.L. Large colorectal adenomas. An approach to pathologic evaluation. Am. J. Clin. Pathol. 2001, 116:336-340.
15. Ge Q.X., Li Y.Y., Nie Y.Q., Zuo W.G., Du Y.L. Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med. Oncol. 2013, 30:535.
16. Hernandez J.M., Farma J.M., Coppola D., Hakam A., Fulp W.J., Chen D.T., et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin. Colorectal Cancer 2011, 10(3):188-193.
17. Hodorová I., Rybárová S., Solár P., Vecanová J., Mihalik J., Bohuš P., et al. Multidrug resistance proteins in renal cell carcinoma. Folia Biol. (Praha) 2008, 54(6):187-192.
18. Kaur G., Masoud A., Raihan N., Radzi M., Khamizar W., Kam L.S. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma. Indian J. Med. Res. 2011, 134:186-192.
19. Kawasaki H., Toyoda M., Shinohara H., Okuda J., Watanabe I., Yamamoto T., et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91(11):2026-2032.
20. Kim P.J., Plescia J., Clevers H., Fearon E.R., Altieri D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362(9379):205-209.
21. Lanza G., Messerini L., Gafa R., Risio M. Colorectal tumors: the histology report. Digest. Liver Dis. 2011, 43S:344-355.
22. Li F., Yang J., Ramnath N., Javle M.M., Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int. J. Cancer 2005, 114:509-512.
23. Lin L.-J., Zheng C.H.-Q., Jin Y., Ma Y., Jiang W.-G., Ma T. Expression of survivin protein in human colorectal carcinogenesis. World J. Gastroenterol. 2003, 9(5):974-977.
24. Liska J., Repiska V., Galbavy S., Polak S., Varga I., Blasko M., et al. Prostate tumours - histological classification and molecular aspects of prostate tumorigenesis. Endocr. Regul. 2007, 41(1):45-57.
25. Na W., Jang S.M., Jun Y.J., Song Y.S., Jang K.-S., Lee K.H., et al. Clinicopathologic significance of survivin expression in colorectal adenocarcinoma. Basic Appl. Pathol. 2009, 2(3):94-100.
26. Oh J.W., Yang W.I., Lee M.J., Park S., Park B.W., Lee K.S. The prognostic significance of survivin expression in breast cancer. J. Breast Cancer 2009, 12(4):285-294.
27. Piras F., Murtas D., Minerba L., Ugalde J., Floris C., Maxia C., et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007, 50:835-842.
28. Qumseya B.J., Coe S., Wallace M.B. The effect of polyp location and patient gender on the presence of dysplasia in colonic polyps. Clin. Transl. Gastroenterol. 2012, 3(7):e20. 10.1038/ctg.2012.14.
29. Tanaka T. Colorectal carcinogenesis: review of human and experimental animal studies. J. Carcinog. 2009, 8:5.
30. Toll A.D., Fabius D., Hyslop T., Pequignot E., DiMarino A.J., Infantolino A., et al. Prognostic significance of high-grade dysplasia in colorectal adenomas. Colorectal Dis. 2011, 13(4):370-373.
31. Valarini S.B.M., Bortoli V.T., Wassano N.S., Pukanski M.F., Maggi D.C., Bertollo L.A. Correlation between location, size and histologic type of colorectal polyps at the presence of dysplasia and adenocarcinoma. J. Coloproctol. (Rio J.) 2011, 31(3).
32. Xiaoyuan C., Longbang C., Jinghua W., Xiaoxiang G., Huaicheng G., Qun Z., et al. Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir. J. Med. Sci. 2009, 179(3):327-335.
33. Yang D.-D., Wu X.-L., He K., Jia G.-H., Wang L.-K. Expression and clinical significance of survivin in colorectal cancer, adenoma and normal colorectal tissues. Mil. Med. Sci. 2013, 7. 525-528, 534.